regulatory
confidence high
sentiment positive
materiality 0.85
FDA approves Ligand's ZELSUVMI for molluscum contagiosum in adults and children 1+
LIGAND PHARMACEUTICALS INC
- FDA approved ZELSUVMI (berdazimer topical gel, 10.3%) for molluscum contagiosum in patients 1 year and older.
- First novel drug for molluscum and first topical prescription that can be applied at home.
- Approximately 6 million Americans infected annually; up to 73% of children go untreated.
- Product expected to be available in the U.S. in the second half of 2024.